Insight Molecular Diagnostics Free Cash Flow 2014-2025 | IMDX
Insight Molecular Diagnostics free cash flow from 2014 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Insight Molecular Diagnostics Annual Free Cash Flow | |
|---|---|
| 2024 | -21.23 |
| 2023 | -23.25 |
| 2022 | -49.91 |
| 2021 | -38.19 |
| 2020 | -27.21 |
| 2019 | -20.63 |
| 2018 | -11.68 |
| 2017 | -13.48 |
| 2016 | -7.63 |
| 2015 | -4.73 |
| 2014 | -1.17 |
| 2013 | -0.74 |
| Insight Molecular Diagnostics Quarterly Free Cash Flow | |
|---|---|
| 2025-06-30 | -12.79 |
| 2025-03-31 | -6.17 |
| 2024-12-31 | -21.23 |
| 2024-09-30 | -15.66 |
| 2024-06-30 | -10.02 |
| 2024-03-31 | -3.85 |
| 2023-12-31 | -23.25 |
| 2023-09-30 | -18.56 |
| 2023-06-30 | -15.01 |
| 2023-03-31 | -8.30 |
| 2022-12-31 | -49.91 |
| 2022-09-30 | -39.46 |
| 2022-06-30 | -27.20 |
| 2022-03-31 | -14.84 |
| 2021-12-31 | -38.19 |
| 2021-09-30 | -30.72 |
| 2021-06-30 | -19.35 |
| 2021-03-31 | -10.68 |
| 2020-12-31 | -27.21 |
| 2020-09-30 | -20.90 |
| 2020-06-30 | -14.37 |
| 2020-03-31 | -6.91 |
| 2019-12-31 | -20.63 |
| 2019-09-30 | -14.43 |
| 2019-06-30 | -9.58 |
| 2019-03-31 | -6.73 |
| 2018-12-31 | -11.68 |
| 2018-09-30 | -9.22 |
| 2018-06-30 | -6.73 |
| 2018-03-31 | -2.76 |
| 2017-12-31 | -13.48 |
| 2017-09-30 | -10.13 |
| 2017-06-30 | -6.63 |
| 2017-03-31 | -3.31 |
| 2016-12-31 | -7.63 |
| 2016-09-30 | -5.03 |
| 2016-06-30 | -3.98 |
| 2016-03-31 | -2.18 |
| 2015-12-31 | -4.72 |
| 2015-09-30 | -2.55 |
| 2015-06-30 | -1.16 |
| 2015-03-31 | -0.18 |
| 2014-12-31 | |
| 2013-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.072B | $0.002B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $46.824B | 59.57 |
| Tempus AI (TEM) | United States | $13.255B | 0.00 |
| Doximity (DOCS) | United States | $12.564B | 55.90 |
| Hims & Hers Health (HIMS) | United States | $10.250B | 83.98 |
| IRhythm Technologies (IRTC) | United States | $5.398B | 0.00 |
| Hinge Health (HNGE) | United States | $4.325B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.713B | 39.89 |
| Privia Health (PRVA) | United States | $2.625B | 194.46 |
| Heartflow (HTFL) | $2.547B | 0.00 | |
| Phreesia (PHR) | United States | $1.833B | 0.00 |
| Enovis (ENOV) | United States | $1.782B | 9.42 |
| 10x Genomics (TXG) | United States | $1.747B | 0.00 |
| Omnicell (OMCL) | United States | $1.503B | 28.96 |
| Schrodinger (SDGR) | United States | $1.446B | 0.00 |
| Azenta (AZTA) | United States | $1.401B | 61.14 |
| Clover Health Investments (CLOV) | United States | $1.368B | 0.00 |
| Claritev (CTEV) | United States | $1.196B | 0.00 |
| Evolent Health (EVH) | United States | $1.089B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.657B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.585B | 0.00 |
| Veradigm (MDRX) | United States | $0.536B | 0.00 |
| Standard BioTools (LAB) | United States | $0.493B | 0.00 |
| Talkspace (TALK) | United States | $0.447B | 133.50 |
| Butterfly Network (BFLY) | United States | $0.400B | 0.00 |
| Carlsmed (CARL) | United States | $0.365B | 0.00 |
| TruBridge (TBRG) | United States | $0.300B | 52.66 |
| Outset Medical (OM) | United States | $0.251B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.246B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.228B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.218B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.197B | 0.00 |
| CapsoVision (CV) | United States | $0.184B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.171B | 0.00 |
| CareCloud (CCLD) | United States | $0.156B | 7.08 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.127B | 0.00 |
| American Well (AMWL) | United States | $0.113B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.084B | 0.00 |
| Pulmonx (LUNG) | United States | $0.072B | 0.00 |
| 111 (YI) | China | $0.061B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.057B | 0.00 |
| HeartBeam (BEAT) | United States | $0.039B | 0.00 |
| Zhongchao (ZCMD) | China | $0.025B | 0.00 |
| Precipio (PRPO) | United States | $0.023B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.016B | 0.00 |
| PROFUSA (PFSA) | United States | $0.014B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.013B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| HeartSciences (HSCS) | United States | $0.008B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.007B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.005B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |